
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
almost 26 years ago
Participating Facultyalmost 26 years ago
Introductionalmost 26 years ago
Overview of Enoxaparin in the Treatment of DVTalmost 26 years ago
CME/CPE Article: Economics of Low-Molecular Weight Heparinsalmost 26 years ago
CME/CPE Quizalmost 26 years ago
Selected Abstracts





